Trial · NCT07172269
Mangosteen Supplement as Adjuvant Therapy With Sitagliptin/Metformin in Iraqi Patients With Type 2 Diabetes
NCT07172269, Not applicable, Completed, Mais Qais Hbeeb
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Mangosteen Supplement as Adjuvant Therapy With Sitagliptin/Metformin in Iraqi Patients With Type 2 Diabetes. Trials, record NCT07172269. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07172269
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Mangosteen Supplement as Adjuvant Therapy With Sitagliptin/Metformin in Iraqi Patients With Type 2 Diabetes
- NCT number
- NCT07172269
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 58 participants, actual
- Lead sponsor
- Mais Qais Hbeeb
- Conditions
- Diabete Mellitus, Type 2 Diabetes, Obesity Type 2 Diabetes Mellitus, Dyslipidemia in Patients With Diabetes Mellitus, Insulin Resistance
- Interventions
- Sitagliptin + Metformin, mangosteen supplement, Lifestyle Management
- First posted
- 2025-09-15
- Last updated
- 2025-09-15
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Hemoglobin A1c (HbA1c) | baseline and after 12 weeks | HbA1c level will be measured using an immunoassay method (Roche Cobas c111 system) to assess glycemic control. |
| Secondary | Change in HOMA-IR (Insulin Resistance Index) | baseline and 12 weeks | Calculated using fasting glucose and fasting insulin levels |
| Secondary | Change in Fasting Blood Glucose (FBG) | Baseline and 12 weeks | Measured by enzymatic hexokinase method (Roche Cobas c111 analyzer) |
| Secondary | Change in HOMA-B (β-cell Function Index) | Baseline and 12 weeks | Calculated using fasting insulin and fasting glucose concentrations |
| Secondary | Change in Lipid Profile (TC, LDL-C, HDL-C, TG, VLDL-C) | Baseline and 12 weeks | Measured by enzymatic colorimetric methods (Roche Cobas c111) |
| Secondary | Change in Serum Interleukin-6 (IL-6) | Baseline and 12 weeks | Measured by ELISA (sandwich principle) |
| Secondary | Change in Serum Superoxide Dismutase-1 (SOD1 | Baseline and 12 weeks | Measured by competitive ELISA kit |
| Secondary | Change in Liver Enzymes (AST, ALT, ALP) | Baseline and 12 weeks | Measured by Roche Cobas c111 analyzer |
| Secondary | Change in Kidney Function (Serum Creatinine, Urea, and Urinary ACR) | Baseline and 12 weeks | Measured by Roche Cobas c111 analyzer and Combilyzer 13 system |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07172269
GET https://conductscience.org/api/trials/v1/NCT07172269/registered